Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR 2.800
+0.090 (3.32%)
Mar 4, 2026, 2:40 PM CET
Oryzon Genomics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | - | -3.79 | -3.71 | -4.52 | -5.33 | Upgrade
|
| Depreciation & Amortization | - | 0.13 | 0.14 | 0.16 | 0.15 | Upgrade
|
| Other Amortization | - | 0.02 | 0.03 | 0.02 | 0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | 0 | Upgrade
|
| Other Operating Activities | - | -1.15 | 3.74 | 1.03 | -1.39 | Upgrade
|
| Change in Accounts Receivable | - | 0.01 | 0.37 | 0.31 | -0.12 | Upgrade
|
| Change in Inventory | - | 0 | 0 | 0.1 | 0.24 | Upgrade
|
| Change in Accounts Payable | - | -0.95 | -1.25 | 0.93 | 1.38 | Upgrade
|
| Change in Other Net Operating Assets | - | -0.16 | 0.03 | 0 | 0.93 | Upgrade
|
| Operating Cash Flow | - | -5.89 | -0.64 | -1.97 | -4.12 | Upgrade
|
| Capital Expenditures | - | - | - | -0.08 | -0.2 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -7.98 | -16.03 | -15.17 | -13.18 | Upgrade
|
| Other Investing Activities | - | -0.11 | -0 | -0 | 0.04 | Upgrade
|
| Investing Cash Flow | - | -8.09 | -16.03 | -15.25 | -13.33 | Upgrade
|
| Short-Term Debt Issued | - | 7.25 | 15.22 | 9.57 | - | Upgrade
|
| Long-Term Debt Issued | - | 6.76 | 1.93 | 5.47 | 9.05 | Upgrade
|
| Total Debt Issued | - | 14.01 | 17.15 | 15.04 | 9.05 | Upgrade
|
| Short-Term Debt Repaid | - | - | -0.9 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -8.44 | -7.52 | -4.73 | -4.36 | Upgrade
|
| Total Debt Repaid | - | -8.44 | -8.42 | -4.73 | -4.36 | Upgrade
|
| Net Debt Issued (Repaid) | - | 5.56 | 8.73 | 10.3 | 4.69 | Upgrade
|
| Issuance of Common Stock | - | 0.07 | - | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | -1.99 | -1.07 | - | Upgrade
|
| Other Financing Activities | - | 1.48 | -0.09 | 0.07 | - | Upgrade
|
| Financing Cash Flow | - | 7.11 | 6.66 | 9.31 | 4.69 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -0.01 | -0 | 0 | 0.4 | Upgrade
|
| Net Cash Flow | - | -6.87 | -10.01 | -7.92 | -12.37 | Upgrade
|
| Free Cash Flow | - | -5.89 | -0.64 | -2.06 | -4.32 | Upgrade
|
| Free Cash Flow Margin | - | -77.32% | -4.05% | -12.25% | -35.82% | Upgrade
|
| Free Cash Flow Per Share | - | -0.09 | -0.01 | -0.04 | -0.08 | Upgrade
|
| Cash Interest Paid | - | 0.39 | 0.44 | 0.34 | 0.29 | Upgrade
|
| Cash Income Tax Paid | - | - | -5.16 | -2.65 | -1.48 | Upgrade
|
| Levered Free Cash Flow | - | -14.23 | -20.58 | -17.29 | -17.89 | Upgrade
|
| Unlevered Free Cash Flow | - | -13.44 | -19.27 | -16.54 | -17.56 | Upgrade
|
| Change in Working Capital | - | -1.1 | -0.84 | 1.34 | 2.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.